OPK Stock Analysis: Buy, Sell, or Hold?
OPK - Opko Health Inc.
$1.10
-0.01 (-0.90%)
▼
5d:
-1.79%
30d:
-6.78%
90d:
-9.09%
HOLD
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Smart Money Accumulation
OPK is down 7.8% this week, but smart money is accumulating calls. Top strike: $1.5 2026-06-18 with 2,828 OI. Call ratio: 100% View Scanner →
Strength: 7.3/10
Get Alerted When OPK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called OPK this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OPK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: OPK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: OPK is currently trading at $1.10, which is considered oversold relative to its 30-day fair value range of $1.12 to $1.21.
Technical Outlook: Technically, OPK is in a strong downtrend. The price is currently testing key support at $1.08. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: OPK has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.76 (+241.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OPK is in a strong downtrend. The price is currently testing key support at $1.08. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: OPK has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.76 (+241.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.12 -
$1.21
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 241.8% below Wall St target ($3.76)
Trading Range Analysis
30-Day Trading Range
$1.12 -
$1.21
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.08
Resistance Level
$1.15
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.44
Wall Street Target
$3.76
(+241.8%)
Revenue Growth (YoY)
-17.2%
Earnings Growth (YoY)
-12.6%
Profit Margin
-36.6%
Share & Embed Analysis
Last updated: May 14, 2026 5:38 PM ET
Data refreshes hourly during market hours. Next update: 6:38 PM
Data refreshes hourly during market hours. Next update: 6:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OPK showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
John A Paganelli
BUY
10000 shares
2026-03-20
Phillip Md Et Al Frost
BUY
580000 shares
2025-11-21
Phillip Md Et Al Frost
BUY
580000 shares
2025-11-19
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$620 | 55 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$250 | 58 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$130 | 59 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 58 HOLD |
